Skip to main content

Advertisement

SpringerLink
Log in

Recent advances in chemotherapy for advanced gastric cancer in Japan

  • Review Article
  • Published:
Surgery Today Aims and scope Submit manuscript

Abstract

In the early 1990s, a combination of 5-fluorouracil (5-FU) and cisplatin was widely adopted to treat advanced gastric cancer; however, no survival advantage over single-agent 5-FU was confirmed by the results of randomized trials conducted over a long period. Recently developed agents such as irinotecan, taxanes (docetaxel), and new oral fluorouracil (S-1) have yielded more promising results, with a response rate of over 50% and a median survival time of over 10 months in combination studies. These newer combination regimens were investigated in various randomized phase III studies to clarify if the newer-generation regimens provided a survival advantage over the oldergeneration regimens. Based on the findings of a large randomized study, S-1 has become standard in the adjuvant setting after D2 dissection curatively resected stage II and III gastric cancer. This article reviews the recent advances in gastric cancer chemotherapy, especially in Japan.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Tsukuma H, editor. Progress report of the Research Group for Population-based Cancer Registration in Japan. 2002.

  2. Kitagawa T, Tsukuma H, Tominaga S, editors. Prediction of cancer incidence in Japan. Cancer Statistics 1999. Tokyo: Shinohara Shuppan; 1999.

    Google Scholar 

  3. Comis S. Integration of chemotherapy into combined modality treatment of solid tumors. Cancer Treat Rev 1974;1:221–238.

    Article  Google Scholar 

  4. Cocconi G, DeLisi V, DiBlasio B: Randomized comparison of 5-FU alone or combined with mitomycin and cytarabine (MFC)in the treatment of advanced gastric cancer. Cancer Treat Rep 1982;66:1263–1266.

    CAS  PubMed  Google Scholar 

  5. The Gastrointestinal Tumor Study Group. Phase II/III chemotherapy studies in advanced gastric cancer. Cancer Treat Rep 1979;63:1871–1876.

    Google Scholar 

  6. Moertel CG, Lavin PT. Phase II/III chemotherapy studies in advanced gastric cancer. Cancer Treat Rep 1979;63:1863–1869.

    CAS  PubMed  Google Scholar 

  7. Preusser P, Achterrath W, Wilke H, Lenaz L, Fink U, Heinicke A, et al. Chemotherapy of gastric cancer. Cancer Treat Rev 1988;15:257–277.

    Article  CAS  PubMed  Google Scholar 

  8. Murad AM, Santiago FF, Petroianu A, Rocha PR, Rodrigues MA, Rausch M. Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 1993;72:37–41.

    Article  CAS  PubMed  Google Scholar 

  9. Pyrhonen S, Kuitunen T, Nyandoto P, Kouri M. Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 1995;71:587–591.

    CAS  PubMed  Google Scholar 

  10. Waters JS, Norman A, Cunningham D, Scarffe JH, Webb A, Harper P, et al. Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: Results of a randomized trial. Br J Cancer 1999;80:269–272.

    Article  CAS  PubMed  Google Scholar 

  11. Moiseyenko VM, Ajani JA, Tjulandin SA, Majlis A, Constenia M, Boni C, et al. Final results of a randomized controlled phase III trial (TAX 325) comparing docetaxel (T) combined with cisplatin (C) and 5-fluorouracil (F) to CF in patients (pts) with metastatic gastric adenocarcinoma (MGC). In: ASCO 2005 (abstract 4002).

  12. Ohtsu A, Shimada Y, Shirao K, Boku N, Hyodo I, Saito H, et al. Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205). J Clin Oncol 2003;21:54–59.

    Article  CAS  PubMed  Google Scholar 

  13. Sakata Y, Ohtsu A, Horikoshi N, Sugimachi K, Mitachi Y, Taguchi T. Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients. Eur J Cancer 1998;34:1715–1720.

    Article  CAS  PubMed  Google Scholar 

  14. Boku N, Ohtsu A, Shimada Y, Sirao K, Seki S, Saito H, et al. Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer. J Clin Oncol 1999;17:319–323.

    CAS  PubMed  Google Scholar 

  15. Koizumi W, Tanabe S, Saigenji K, Ohtsu A, Boku N, Nagashima F, et al. Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer. Br J Cancer 2003;89(12):2207–2212.

    Article  CAS  PubMed  Google Scholar 

  16. Komatsu Y, Yuki S, Tateyama M, Kudo M, Asaka M. Irinotecan plus oral S-1 in patients with advanced gastric cancer-biweekly IRIS regimen (in Japanese with English abstract). Gan to Kagaku Ryoho (Jpn J Cancer Chemother) 2006;33 suppl 1:131–134.

    Google Scholar 

  17. Yoshida K, Ninomiya M, Takakura N, Hirabayashi N, Takiyama W, Sato Y, et al. Phase II study of docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer. Clin Cancer Res 2006;12:3042–3047.

    Article  Google Scholar 

  18. Yamaguchi K, Shimamura T, Hyodo I, Koizumi W, Doi T, Narahara H, et al. Phase I/II study of docetaxel and S-1 in patients with advanced gastric cancer. Br J Cancer 2006;94:1803–1808.

    Article  CAS  PubMed  Google Scholar 

  19. Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): A phase III trial. Lancet Oncol 2008;9(3):215–221.

    Article  CAS  PubMed  Google Scholar 

  20. Imamura H, IIishi H, Tsuburaya A, Hatake K, Imamoto H, Esaki T, et al. Randomized phase III study of irinotecan plus S-1 (IRIS) versus S-1 alone as first-line treatment for advanced gastric cancer (GC0301/TOP-002). In: ASCO GI 2008; Abstract #5.

  21. Fujii M. Chemotherapy for advanced gastric cancer: ongoing phase III study of S-1 alone versus S-1 and docetaxel combination (JACCRO GC03 study). Int J Clin Oncol 2008;13:201–205.

    Article  CAS  PubMed  Google Scholar 

  22. Nakayama N, Koizumi W, Sasaki T, Higuchi K, Tanabe S, Nishimura K, et al. A multicenter, phase I dose-escalating study of docetaxel, cisplatin and S-1 for advanced gastric cancer (KDOG0601). Oncology 2008;75(1–2):1–7.

    Article  CAS  PubMed  Google Scholar 

  23. Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 2007;357:1810–1820.

    Article  CAS  PubMed  Google Scholar 

  24. Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001;345:725–730.

    Article  CAS  PubMed  Google Scholar 

  25. Nakajima T, Kinoshita T, Nashimoto A, Sairenji M, Yamaguchi T, Sakamoto J, et al. Randomized controlled study of adjuvant uracil-tegafur versus surgery alone for serosa-negative, locally advanced gastric cancer. Br J Surg 2007;94:1468–1476.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Digestive Surgery, Nihon University School of Medicine, 1-8-13 Kandasurugadai, Chiyoda-ku, Tokyo, 101-8309, Japan

    Masashi Fujii, Mitsugu Kochi & Tadatoshi Takayama

Authors
  1. Masashi Fujii
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mitsugu Kochi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tadatoshi Takayama
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fujii, M., Kochi, M. & Takayama, T. Recent advances in chemotherapy for advanced gastric cancer in Japan. Surg Today 40, 295–300 (2010). https://doi.org/10.1007/s00595-009-4148-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00595-009-4148-9

Key words

Search

Navigation